Lixte Biotechnology Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIXT research report →
Companylixte.com
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.
- CEO
- Geordan G. Pursglove
- IPO
- 2007
- Employees
- 2
- HQ
- Pasadena, CA, US
Price Chart
Valuation
- Market Cap
- $69.34M
- P/E
- -8.38
- P/S
- 0.00
- P/B
- 7.68
- EV/EBITDA
- -9.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -125.56%
- ROIC
- -62.41%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,009,520 · -67.58%
- EPS
- $-1.26 · 20.75%
- Op Income
- $-5,107,621
- FCF YoY
- 2.97%
Performance & Tape
- 52W High
- $6.26
- 52W Low
- $0.64
- 50D MA
- $3.55
- 200D MA
- $3.94
- Beta
- 1.05
- Avg Volume
- 48.96K
Get TickerSpark's AI analysis on LIXT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 15, 26 | Pursglove Geordan Garrett | other | 350,000 |
| Apr 15, 26 | Pursglove Geordan Garrett | sell | 350,000 |
| Apr 15, 26 | Stazzone Peter | other | 50,000 |
| Apr 15, 26 | Stazzone Peter | sell | 50,000 |
| Apr 15, 26 | Sawyer Jason David | other | 25,000 |
| Apr 15, 26 | Felix Lourdes | other | 25,000 |
| Apr 15, 26 | Felix Lourdes | sell | 25,000 |
| Apr 15, 26 | Sawyer Jason David | sell | 25,000 |
| Apr 15, 26 | Primus Guy Warren | other | 25,000 |
| Apr 15, 26 | Holloway Michael Andrew | other | 25,000 |
Our LIXT Coverage
We haven't published any research on LIXT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIXT Report →